# A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

> **NCT07260669** · PHASE2 · RECRUITING · sponsor: **Gesynta Pharma AB** · enrollment: 190 (estimated)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Vipoglanstat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07260669
- **Lead sponsor:** Gesynta Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07260669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07260669, "A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07260669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*